Journalartikel

Jahr der Veröffentlichung: 2016

Seiten: 755-766

Zeitschrift: Expert Review of Respiratory Medicine

Bandnummer: 10

Heftnummer: 7

ISSN: 1747-6348

eISSN: 1747-6356

DOI Link: https://doi.org/10.1080/17476348.2016.1190275

Verlag: Taylor and Francis Group

Abstract: 

Introduction: Chronic obstructive pulmonary disease is the fourth leading cause of death worldwide, one serious complication being pulmonary hypertension, which occurs in up to 30% of patients and increases mortality drastically. Difficulties in diagnosis and the unclear beneficial effects of PH-specific therapy have hitherto resulted in the absence of approved therapies. Consequently, PH and right heart failure in COPD are still currently treated according to symptoms and not underlying cause

Areas covered: This review focuses on the current knowledge of its pathogenesis, clinical picture, diagnosis as well as methods for treatment

Expert commentary: Since PH-COPD is an orphan disease with grievous consequences, and diagnosis as well as the right choice of possible treatment is crucial, referral to an expert center in cases of suspicion is necessary. Hitherto there is no officially approved treatment available even though several studies have shown notable improvement in selected individuals, making diagnostics, prognostic markers, and the search for therapeutic agents key issues of interest in this field

Harvard-Zitierstil: Grimminger, J., Ghofrani, H., Weissmann, N., Klose, H. and Grimminger, F. (2016) COPD-associated pulmonary hypertension: clinical implications and current methods for treatment, Expert Review of Respiratory Medicine, 10(7), pp. 755-766. https://doi.org/10.1080/17476348.2016.1190275

APA-Zitierstil: Grimminger, J., Ghofrani, H., Weissmann, N., Klose, H., & Grimminger, F. (2016). COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. Expert Review of Respiratory Medicine. 10(7), 755-766. https://doi.org/10.1080/17476348.2016.1190275